Recent Company News

• 08:41 AM ET Jul 10, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:10 AM ET Jul 10, 2026
  

  FDA approves Sarclisa Escena (subcutaneous) for multiple myeloma indications (€76.40, -0.08)

• 11:46 AM ET Jul 09, 2026
  

  StreetAccount Summary - U.S. Unusual Option Volume: VIX (3.6%) to 16.29; S&P 500 +0.5% to 7,522.76

• 06:48 AM ET Jul 09, 2026
  

  Street Takeaways - AstraZeneca ~(9%) lower as PIII CARDIO-TTRansform of Wainua in ATTR-CM did not meet primary endpoint (12840.0000p, -1400)

• 04:26 AM ET Jul 09, 2026
  

  European momentum unwinds as markets question AI infrastructure returns:

• 09:26 PM ET Jul 08, 2026
  

  NICE recommends MacroGenics's Tzield to delay onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes ($4.66, 0.00)

• 09:20 PM ET Jul 08, 2026
  

  NICE recommends Regeneron's Libtayo to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy ($662.88, 0.00)

• 08:48 AM ET Jul 08, 2026
  

  ESG Daily - Fed plans new AML rules; Apple loses EU DMA challenge; S.Korea mandates ESG disclosures

• 08:25 AM ET Jul 08, 2026
  

  StreetAccount Themes Headlines (8-Jul)

• 06:07 AM ET Jul 08, 2026
  

  EU Commission seeks feedback on commitments offered by Sanofi over possible anticompetitive conduct regarding the promotion of a flu vaccine for vulnerable patients (€74.72, -1.06)